Cargando…
Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype
Direct-acting antivirals with or without peginterferon α (PEG-IFN α) plus ribavirin are now available for the treatment of hepatitis C virus (HCV) infection. Direct-acting antivirals are potent inhibitors of HCV replication, but some of them occasionally possess serious adverse events. We experience...
Autores principales: | Kanda, Tatsuo, Nakamura, Masato, Sasaki, Reina, Yasui, Shin, Nakamoto, Shingo, Haga, Yuki, Jiang, Xia, Wu, Shuang, Tawada, Akinobu, Arai, Makoto, Imazeki, Fumio, Yokosuka, Osamu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520186/ https://www.ncbi.nlm.nih.gov/pubmed/26269697 http://dx.doi.org/10.1159/000437138 |
Ejemplares similares
-
Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy
por: Nakamoto, Shingo, et al.
Publicado: (2015) -
Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy
por: Nakamoto, Shingo, et al.
Publicado: (2017) -
Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin
por: Miyamura, Tatsuo, et al.
Publicado: (2012) -
Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin
por: Kanda, Tatsuo, et al.
Publicado: (2016) -
Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
por: Kanda, Tatsuo, et al.
Publicado: (2017)